-
EP3326621
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3326621
| EP3326621 - ORAL PHARMACEUTICAL DOSAGE FORMS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 17.04.2020 Database last updated on 13.07.2024 | |
| Former | Examination is in progress Status updated on 30.10.2019 | ||
| Former | Request for examination was made Status updated on 16.11.2018 | ||
| Former | The application has been published Status updated on 27.04.2018 | Most recent event Tooltip | 17.04.2020 | Withdrawal of application | published on 20.05.2020 [2020/21] | Applicant(s) | For all designated states Durect Corporation 10260 Bubb Road Cupertino, CA 95014 / US | [2018/22] | Inventor(s) | 01 /
YUM, Su Il 2 Results Way Cupertino, CA California 95014-4166 / US | 02 /
CHAO, Wendy 2 Results Way Cupertino, CA California 95014-4166 / US | 03 /
SU, Huey Ching 2 Results Way Cupertino, CA California 95014-4166 / US | 04 /
FU, Robert 2211 Bridgepointe Parkway Suite 500 San Mateo, CA California 94404 / US | 05 /
ZAMLOOT, Michael 2211 Bridgepointe Parkway Suite 500 San Mateo, CA California 94404 / US | [2018/22] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2018/22] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 17208877.5 | 05.12.2008 | [2018/22] | Priority number, date | US20070005681P | 06.12.2007 Original published format: US 5681 P | US20070005685P | 06.12.2007 Original published format: US 5685 P | US20080198201P | 03.11.2008 Original published format: US 198201 P | [2018/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3326621 | Date: | 30.05.2018 | Language: | EN | [2018/22] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 20.02.2018 | Classification | IPC: | A61K9/48, A61K31/137, A61K31/4402, A61K31/485 | [2018/22] | CPC: |
A61K9/4866 (EP,US);
A61K31/137 (EP,US);
A61K31/4402 (EP,US);
A61K31/4458 (EP,US);
A61K31/485 (EP,US);
A61K9/48 (US);
A61K9/4858 (EP,US);
A61P19/00 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/20 (EP);
A61P25/24 (EP);
A61P25/26 (EP);
A61P25/36 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2018/51] |
| Former [2018/22] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | Title | German: | ORALE ARZNEIMITTELDOSIERFORMEN | [2018/22] | English: | ORAL PHARMACEUTICAL DOSAGE FORMS | [2018/22] | French: | FORMES ORALES DE DOSAGE PHARMACEUTIQUE | [2018/22] | Examination procedure | 12.11.2018 | Examination requested [2018/51] | 12.11.2018 | Date on which the examining division has become responsible | 10.01.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 18.03.2019 | Amendment by applicant (claims and/or description) | 05.11.2019 | Despatch of a communication from the examining division (Time limit: M06) | 15.04.2020 | Application withdrawn by applicant [2020/21] | Parent application(s) Tooltip | EP08253904.0 / EP2067471 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 18.03.2019 | Request for further processing filed | 18.03.2019 | Full payment received (date of receipt of payment) Request granted | 28.03.2019 | Decision despatched | Fees paid | Renewal fee | 20.12.2017 | Renewal fee patent year 03 | 20.12.2017 | Renewal fee patent year 04 | 20.12.2017 | Renewal fee patent year 05 | 20.12.2017 | Renewal fee patent year 06 | 20.12.2017 | Renewal fee patent year 07 | 20.12.2017 | Renewal fee patent year 08 | 20.12.2017 | Renewal fee patent year 09 | 20.12.2017 | Renewal fee patent year 10 | 31.12.2018 | Renewal fee patent year 11 | 27.12.2019 | Renewal fee patent year 12 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]US6413536 (GIBSON JOHN W [US], et al) [A] 1-20 * column 2, line 55 - column 3, line 64 * * column 10, line 72 - column 11, line 53 * * column 16, lines 4-16 *; | [A]WO03013476 (EURO CELTIQUE SA [LU], et al) [A] 1-20 * the whole document *; | [XY]WO03055475 (LEK PHARMACEUTICALS [SI], et al) [X] 1,9,19 * page 2, lines 7-36 * * pages 5-12 * * examples 1-5 * * claims 1-36 * [Y] 1-20; | [XY]WO2004054542 (DURECT CORP [US], et al) [X] 1,2,5,6,9-13,19,20 * page 5, lines 1-29 * * page 8 - page 10 * * page 15, line 30 - page 16, line 10 * * page 22, lines 21-25 * * page 23, lines 16-33 * * pages 31,32 * * table 1 * * figures 1-4,7 * [Y] 1-20; | [A]WO2004056337 (PAIN THERAPEUTICS [US], et al) [A] 1-20 * page 4, paragraph 8 * * page 8, paragraph 17 * * page 30, paragraph 64 * * pages 31-35,41 * * page 60, paragraphs 164,165 * * page 62, paragraphs 168,169 *; | [A]US2006115527 (HASSAN EMADELDIN M [US], et al) [A] 1-20 * the whole document * * examples 26,27 ** page 1, column L, paragraph 1 *; | [A] - SULLIVAN S A ET AL, "SUSTAINED RELEASE OF ORALLY ADMINISTERED ACTIVE USING SABER DELIVERY SYSTEM INCORPORATED INTO SOFT GELATIN CAPSULES", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS,, (19980101), no. 25, ISSN 1022-0178, page 918/919, XP008030849 [A] 1-20 * the whole document * | by applicant | US5747058 | US5968542 | US6413536 | US6498153 | US2004161382 | US2007027105 | - THEEUWES et al., Journal of Pharmaceutical Sciences, (19770000), vol. 66, no. 10, pages 1388 - 1392 | - REMINGTON, Pharmaceutical Sciences, Mack Publishing Co. | - BURGER, Medical Chemistry, Wiley-Interscience, vol. 1 and 2 | - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19 | - SAVAGE et al., Addict Sci Clin Pract, (20080000), vol. 4, no. 2, pages 4 - 25 | - MARSCH et al., J Pharmacol Exp Ther, (20010000), vol. 299, no. 3, pages 1056 - 1065 | - WEBSTER LR, Emerging opioid formulations: abuse deterrent or abuse resistant?, (20070000), URL: http:www.emergingsolutionsinpain.comlopencms/esp/commentaries/index.html |